109 results
Page 2 of 6
8-K
EX-99.1
60o ssk1l
26 Mar 24
Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones
4:05pm
8-K
EX-99.1
01jcrz serirocq4qq1r
4 Mar 24
Regulation FD Disclosure
5:25pm
8-K
EX-99.1
wdi6j
8 Jan 24
Regulation FD Disclosure
4:09pm
8-K
EX-1.1
lwhavw9t6m4
21 Dec 23
Annexon Announces Pricing of $125.0 Million Underwritten Public Offering of Common Stock
4:09pm
8-K
EX-99.1
6zc1qwfe
21 Dec 23
Annexon Announces Pricing of $125.0 Million Underwritten Public Offering of Common Stock
4:09pm
424B5
m8mbla8m9x4m7ucp0pq
21 Dec 23
Prospectus supplement for primary offering
4:05pm
8-K
EX-99.1
gnjpndoxksl
20 Dec 23
Regulation FD Disclosure
5:17pm
8-K
EX-99.2
bkrm7g05n9npnf8wq
20 Dec 23
Regulation FD Disclosure
5:17pm
8-K
EX-99.1
qo5oihfqjbyg2 mty6uy
13 Nov 23
Annexon Reports Significant Progress with its Priority Programs and Third Quarter 2023 Financial Results
4:10pm
8-K
EX-99.1
ar1ktclvp
24 Oct 23
Annexon Receives Prime Designation from the Ema for ANX007 for the Treatment of Geographic Atrophy
4:30pm
8-K
EX-99.1
j7hcf6g
11 Oct 23
Annexon Announces Clinical and Regulatory Progress for ANX005 Pivotal
4:44pm
8-K
EX-99.1
l9vwucxd oflw3
7 Aug 23
Annexon Highlights Recent Pipeline and Business Progress and Reports Second Quarter 2023 Financial Results
4:12pm
8-K
EX-99.2
twtvhnhy
31 Jul 23
Annexon Biosciences Strengthens Leadership Team with Appointment of Jamie Dananberg, M.D., as Chief Medical Officer
4:30pm
8-K
EX-99.1
51zk2agm51
25 May 23
Other Events
6:08am
8-K
EX-99.1
hhpnvygu94u
8 May 23
Annexon Reports First Quarter 2023 Financial Results and Highlights Recent Pipeline Progress
4:11pm